UMIN-CTR Clinical Trial

Recruitment status Preinitiation
Unique ID issued by UMIN UMIN000049071
Receipt No. R000055907
Scientific Title Effects of imeglimin in patients with type 2 diabetes mellitus
Date of disclosure of the study information 2022/10/01
Last modified on 2022/09/30 (Ver. 1)

* This page includes information on clinical trials registered in UMIN clinical trial registed system.
* We don't aim to advertise certain products or treatments


Basic information
Public title Effects of imeglimin in patients with type 2 diabetes mellitus
Acronym Effects of imeglimin in patients with type 2 diabetes mellitus
Scientific Title Effects of imeglimin in patients with type 2 diabetes mellitus
Scientific Title:Acronym Effects of imeglimin in patients with type 2 diabetes mellitus
Region
Japan

Condition
Condition type 2 diabetes mellitus
Classification by specialty
Medicine in general Endocrinology and Metabolism Geriatrics
Classification by malignancy Others
Genomic information NO

Objectives
Narrative objectives1 To study the effect of imeglimin on various parameters in patients with type 2 diabetes mellitus.
Basic objectives2 Efficacy
Basic objectives -Others
Trial characteristics_1
Trial characteristics_2
Developmental phase

Assessment
Primary outcomes Blood glucose and skeletal muscle related parameters
Key secondary outcomes

Base
Study type Observational

Study design
Basic design
Randomization
Randomization unit
Blinding
Control
Stratification
Dynamic allocation
Institution consideration
Blocking
Concealment

Intervention
No. of arms
Purpose of intervention
Type of intervention
Interventions/Control_1
Interventions/Control_2
Interventions/Control_3
Interventions/Control_4
Interventions/Control_5
Interventions/Control_6
Interventions/Control_7
Interventions/Control_8
Interventions/Control_9
Interventions/Control_10

Eligibility
Age-lower limit
20 years-old <=
Age-upper limit

Not applicable
Gender Male and Female
Key inclusion criteria Patients with type 2 diabetes attending the Department of Diabetes and Metabolism
HbA1c between 7.0% and 10%.
Patients with written consent
Key exclusion criteria Patients with a history of severe ketoacidosis, diabetic coma, or pre-coma
Patients with malignant tumors and other serious diseases with poor prognosis
Impaired renal function: eGFR <45 mL/min/1.73 m2
Target sample size 30

Research contact person
Name of lead principal investigator
1st name satoshi
Middle name
Last name ida
Organization Ise Red Cross Hospital
Division name Department of diabetes and metabolism
Zip code 516-8512
Address 1-471-2, Funae, 1-chome
TEL 0596282171
Email bboy98762006@yahoo.co.jp

Public contact
Name of contact person
1st name satoshi
Middle name
Last name ida
Organization Ise Red Cross Hospital
Division name Department of diabetes and metabolism
Zip code 516-8512
Address 1-471-2, Funae, 1-chome
TEL 0596282171
Homepage URL
Email bboy98762006@yahoo.co.jp

Sponsor
Institute Ise Red Cross Hospital
Institute
Department

Funding Source
Organization Ise Red Cross Hospital
Organization
Division
Category of Funding Organization Self funding
Nationality of Funding Organization

Other related organizations
Co-sponsor
Name of secondary funder(s)

IRB Contact (For public release)
Organization Ethics committee of Ise Red Cross Hospital
Address 1-471-2, Funae, 1-chome, Ise-shi, Mie, 516-8512
Tel 0596282171
Email bboy98762006@yahoo.co.jp

Secondary IDs
Secondary IDs NO
Study ID_1
Org. issuing International ID_1
Study ID_2
Org. issuing International ID_2
IND to MHLW

Institutions
Institutions

Other administrative information
Date of disclosure of the study information
2022 Year 10 Month 01 Day

Related information
URL releasing protocol
Publication of results Unpublished

Result
URL related to results and publications
Number of participants that the trial has enrolled
Results
Results date posted
Results Delayed
Results Delay Reason
Date of the first journal publication of results
Baseline Characteristics
Participant flow
Adverse events
Outcome measures
Plan to share IPD
IPD sharing Plan description

Progress
Recruitment status Preinitiation
Date of protocol fixation
2022 Year 10 Month 01 Day
Date of IRB
2022 Year 09 Month 30 Day
Anticipated trial start date
2022 Year 10 Month 01 Day
Last follow-up date
2023 Year 05 Month 01 Day
Date of closure to data entry
Date trial data considered complete
Date analysis concluded

Other
Other related information None

Management information
Registered date
2022 Year 09 Month 30 Day
Last modified on
2022 Year 09 Month 30 Day


Link to view the page
URL(English) https://center6.umin.ac.jp/cgi-open-bin/ctr_e/ctr_view.cgi?recptno=R000055907